MALLINCKRODT Attività
Numero di dipendenti: 2 786
Dirigenti
| Dirigenti | Titolo | Età | Da |
|---|---|---|---|
| Chief Executive Officer | 55 | 25/06/22 | |
Bryan Reasons
DFI | Director of Finance/CFO | 56 | 18/03/19 |
Kassie Harrold
CMP | Compliance Officer | 45 | - |
Peter Richardson
CTO | Chief Tech/Sci/R&D Officer | 64 | 12/01/23 |
Derek Belz
IRO | Public Communications Contact | - | 01/04/22 |
| Investor Relations Contact | - | 01/01/13 | |
Lisa French
PRN | Corporate Officer/Principal | 55 | - |
Jason Goodson
PRN | Corporate Officer/Principal | 43 | - |
Mark Tyndall
LAW | General Counsel | 48 | 01/06/14 |
| Corporate Officer/Principal | 47 | - |
Amministratori
| Amministratori | Titolo | Età | Da |
|---|---|---|---|
Wesley Wheeler
BRD | Director/Board Member | 68 | 02/02 |
Paul Bisaro
CHM | Chairman | 63 | 16/06/22 |
| Chief Executive Officer | 55 | 25/06/22 | |
David Stetson
BRD | Director/Board Member | 67 | 14/11 |
Shah Hussain
BRD | Director/Board Member | 59 | 02/02 |
Katina Dorton
BRD | Director/Board Member | 66 | 02/02 |
Jon Zinman
BRD | Director/Board Member | 44 | 14/11 |
Classe di azioni
| Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
|---|---|---|---|---|---|
| Azione A | 1 | 19 696 335 | 19 696 335 ( 100,00 %) | 0 | 100,00 % |
Partecipazioni
| Nome | Azioni | % | Valorizzazione |
|---|---|---|---|
SILENCE THERAPEUTICS PLC 4.70% | 5 063 859 | 4.70% | 4 456 196 $ |
Coordinate società
Mallinckrodt Plc
College Business & Technology Park Cruiserath
15, Blanchardstown
+353 1 696 0000
http://mallinckrodt.com
Società del gruppo
| Nome | Categoria e settore |
|---|---|
Sucampo Pharma LLC
 Sucampo Pharma LLC Miscellaneous Commercial ServicesCommercial Services Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan. |
Miscellaneous Commercial Services
|
Sucampo GmbH
 Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The private company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. |
Pharmaceuticals: Major
|
Mallinckrodt Group SARL
| |
Mallinckrodt Windsor SARL
 Mallinckrodt Windsor SARL Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Windsor SARL provides pharmaceutical products. The private company is based in Luxembourg, Luxembourg. |
Pharmaceuticals: Major
|
Mallinckrodt International Holdings SARL
 Mallinckrodt International Holdings SARL Financial ConglomeratesFinance Part of Mallinckrodt Plc, Mallinckrodt International Holdings SARL functions as an investment holding Luxembourger company. The private company is based in Luxembourg, Luxembourg. |
Financial Conglomerates
|
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. |
Pharmaceuticals: Major
|
Settore
| Variaz. 1 gen. | Capi. | |
|---|---|---|
| +25,83% | 661 Mrd | |
| +27,00% | 566 Mrd | |
| -6,76% | 352 Mrd | |
| +20,34% | 332 Mrd | |
| +3,00% | 283 Mrd | |
| +13,09% | 231 Mrd | |
| +5,46% | 200 Mrd | |
| -9,61% | 195 Mrd | |
| -6,26% | 145 Mrd |
